Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Japan’s Ministry of Health, Labour and Welfare has granted approval to Genzyme's Synvisc (hylan G-F 20; 3 x 2ml), for osteoarthritis knee treatment.
Subscribe to our email newsletter
The company intends to introduce Synvisc in Japan by the end of this year.
Further, Genzyme has provided exclusive commercialisation rights to Teijin Pharma for Synvisc in Japan, under an agreement signed between the companies.
Teijin Pharma president Osamu Nishikawa said that doctors and patients will be pleased to have a new product available that provides OA knee pain relief with just three injections rather than multiple injection products which are currently on the market.
“We look forward to utilising our marketing and sales experience in the orthopaedics space to offer physicians and patients this therapeutic option,” Nishikawa said.